Assembly Biosciences (Nasdaq:ASMB) - Stock Price, News & Analysis

ASMB Stock Overview

A biotechnology company, develops therapeutic candidates for the treatment of viral diseases.

ASMB fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 96.9% below our estimate of its fair value

Earnings have grown 4% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 22.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($91M)

Shareholders have been diluted in the past year

Assembly Biosciences, Inc. Competitors

Agenus

NasdaqCM:AGEN

US$113.9m

Precision BioSciences

NasdaqCM:DTIL

US$63.9m

Affimed

NasdaqGM:AFMD

US$60.6m

Elutia

NasdaqCM:ELUT

US$124.7m

Price History & Performance

Summary of all time highs, changes and price drops for Assembly Biosciences
Historical stock prices
Current Share Price	US$14.92
52 Week High	US$20.04
52 Week Low	US$7.69
Beta	0.65
11 Month Change	-1.39%
3 Month Change	-1.58%
1 Year Change	39.70%
33 Year Change	-66.12%
5 Year Change	-89.42%
Change since IPO	-96.05%

Recent updates

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Oct 05

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Jul 20

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jun 08

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jan 11

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Sep 03

Assembly Biosciences announces resignation of CFO

Jun 02

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Mar 24

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

Feb 05

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Dec 14

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Nov 16

Assembly Biosciences EPS beats by $0.69, beats on revenue

Nov 05

Shareholder Returns

	ASMB	US Biotechs	US Market
7D	14.2%	5.3%	4.9%
1Y	39.7%	15.7%	25.6%

Return vs Industry: ASMB exceeded the US Biotechs industry which returned 13.4% over the past year.

Return vs Market: ASMB exceeded the US Market which returned 24.7% over the past year.

Price Volatility

Is ASMB's price volatile compared to industry and market?
ASMB volatility
ASMB Average Weekly Movement	8.4%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ASMB has not had significant price volatility in the past 3 months.

Volatility Over Time: ASMB's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2005	65	Jason Okazaki	www.assemblybio.com

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).

Assembly Biosciences, Inc. Fundamentals Summary

How do Assembly Biosciences's earnings and revenue compare to its market cap?
ASMB fundamental statistics
Market cap	US$90.74m
Earnings (TTM)	-US$45.61m
Revenue (TTM)	US$21.48m

4.4x

P/S Ratio

-2.1x

P/E Ratio

Is ASMB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASMB income statement (TTM)
Revenue	US$21.48m
Cost of Revenue	US$49.97m
Gross Profit	-US$28.49m
Other Expenses	US$17.12m
Earnings	-US$45.61m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-7.19
Gross Margin	-132.61%
Net Profit Margin	-212.33%
Debt/Equity Ratio	0%

How did ASMB perform over the long term?

See historical performance and comparison

ASMB Stock Overview

Rewards

Risk Analysis

Assembly Biosciences, Inc. Competitors

NasdaqCM:AGEN

US$113.9m

NasdaqCM:DTIL

US$63.9m

NasdaqGM:AFMD

US$60.6m

NasdaqCM:ELUT

US$124.7m

Price History & Performance

Recent News & Updates

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop

Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.

Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024

Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024

Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board

Recent updates

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop

Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.

Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024

Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024

Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board

New major risk - Revenue and earnings growth

Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer

New major risk - Share price stability

Assembly Biosciences Receives Non-Compliance Notice from Nasdaq

Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

New major risk - Revenue and earnings growth

Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

New minor risk - Insider selling

Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?

Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

High number of new directors

Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Price target decreased to US$7.38

High number of new directors

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences, Inc. Announces Management Appointments

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Assembly Biosciences, Inc. to Introduce New Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences Inc. Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

High number of new directors

Assembly Biosciences, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Consensus forecasts updated

Price target increased to US$10.90

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.094 loss in 3Q 2020)

Price target decreased to US$9.71

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from Russell Microcap Growth Index

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs At the International Liver Congress™ EASL 2021

CFO & Principal Accounting Officer Thomas Russo has left the company

Assembly Biosciences announces resignation of CFO

Consensus revenue estimates fall to US$6.63m

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Analysts update estimates

Price target lowered to US$11.60

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$6.45

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Assembly Biosciences, Inc. Announces Board Changes, Effective December 31, 2020

Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Analysts increase revenue estimates to US$81.8m

Revenue beats expectations, earnings disappoint